MR-2034

MR-2034, or Mr-2034, also known as (–)-MR-2033, is a selective κ-opioid receptor (KOR) agonist of the benzomorphan family.^[1][2] Unlike other benzomorphan KOR agonists like cyclazocine and alazocine, MR-2034 does not also act on sigma receptors.^[2] In addition to the KOR, it has affinity for the μ-opioid receptor (MOR), but does not activate this receptor.^[2] The drug produces dose-dependent hallucinogenic and dysphoric effects in humans, as well as other effects such as dizziness, anxiety, and sedation.^[3][2] These effects can be blocked by the non-selective opioid receptor antagonist naloxone.^[2] The preceding findings led to the conclusion that the hallucinogenic and dysphoric effects of benzomorphans are mediated by the KOR rather than by sigma receptors.^[2] MR-2034 was first described in the scientific literature by 1975^[4][5] and its hallucinogenic effects in humans were described in 1986.^[2]

Other namesMR2034; Mr-2034; (–)-MR-2033; (–)-MR2033

Drug classκ-Opioid receptor agonist; Hallucinogen

ATC code

• None

CAS Number

• 57236-85-8

Quick facts Clinical data, Other names ...

MR-2034

Clinical data
Other names	MR2034; Mr-2034; (–)-MR-2033; (–)-MR2033
Drug class	κ-Opioid receptor agonist; Hallucinogen
ATC code	None
Identifiers
IUPAC name (1R,9R)-1,13-dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol
CAS Number	57236-85-8
PubChem CID	123980
ChemSpider	110499
CompTox Dashboard (EPA)	DTXSID20972735
Chemical and physical data
Formula	C19H27NO2
Molar mass	301.430 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1[C@H]2CC3=C([C@@]1(CCN2C[C@H]4CCCO4)C)C=C(C=C3)O
InChI InChI=1S/C19H27NO2/c1-13-18-10-14-5-6-15(21)11-17(14)19(13,2)7-8-20(18)12-16-4-3-9-22-16/h5-6,11,13,16,18,21H,3-4,7-10,12H2,1-2H3/t13?,16-,18-,19-/m1/s1 Key:NLKLXMMOJZHSCB-SENCRUMESA-N

Close